Differential regulation of rat peripheral 5-HT2A and 5-HT2B receptor systems:: influence of drug treatment

被引:6
|
作者
Enguix, MJ [1 ]
Saánchez, L [1 ]
Villazón, M [1 ]
Brea, J [1 ]
Tristaán, H [1 ]
Caruncho, HJ [1 ]
Cadavid, MI [1 ]
Loza, MI [1 ]
机构
[1] Univ Santiago de Compostela, Dept Pharmacol, Sch Pharm, Santiago De Compostela 15782, Spain
关键词
(+/-)DOI; clozapine; cyproheptadine; rauwolscine; rat thoracic aorta; rat gastric fundus; 5-HT2A receptor; 5-HT2B receptor; ex vivo treatments;
D O I
10.1007/s00210-003-0775-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Most studies of 5-HT2 receptor regulation have been carried out on the central nervous system (CNS) (which expresses 5-HT2A and 5-HT2C receptors); very few in vitro studies have addressed the peripheral receptors 5-HT2A and 5-HT2B. The aim of this investigation was to compare the possible short- and long-term processes regulating these peripheral receptors in the rat. The in vitro contractile response elicited by serotonin (5-HT, 10 muM) in the rat gastric fundus (5-HT2B receptor system) was rapid and followed by a partial fade to a steady state, in contrast with the rat thoracic aorta response (5-HT2A receptor system), which was more stable, slower and sustained. To characterize drug-receptor interactions, cumulative concentration/response curves (CCRCs) for 5-HT were constructed ex vivo for rat tissues treated with drugs acting at these receptors. Rats were examined 4 or 24 h after a single, i.p. administration of (+/-)1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(+/-)DOI, 1 or 2.5 mg/kg], clozapine, cyproheptadine or rauwolscine (10 mg/kg), 48 h after a single i.p. administration of (+/-)DOI (2.5 mg/kg), clozapine or cyproheptadine (10 mg/kg) or 24 h after the last of with 15 daily i.p. administrations of (+/-)DOI (1 or 2.5 mg/kg), clozapine, cyproheptadine or rauwolscine (10 mg/kg). In the aorta, E-max (the maximum response elicited by 5-HT) was unchanged 4 h after a single dose of any of the drugs tested. However, 24 h after a single dose, E-max was lower in animals treated with (+/-)DOI (2.5 mg/kg), clozapine or cyproheptadine than in controls, whilst 48 h after a single dose of (+/-)DOI (2.5 mg/kg), clozapine or cyproheptadine there was no difference in E-max between experimental and control animals. After chronic treatment with (+/-)DOI (2.5 mg/kg), clozapine and cyproheptadine, E-max was lower than in controls. In the gastric fundus, E-max 4 h after a single dose of each drug was lower than in controls, and the response recovered by 24 or 48 h. Following chronic treatment, E-max was significantly lower than in controls for each drug used. These findings suggest first, that regulation of peripheral 5-HT2 receptors (5-HT2A and 5-HT2B) is a functionally significant phenomenon in vivo, and occurs after administration of both agonists and antagonists. Second, the kinetics of peripheral 5-HT2 receptor regulation were similar in both in vivo and ex vivo experiments. The 5-HT2B receptors in rat gastric fundus are more sensitive to drug-induced regulation than the 5-HT2A rat aortic receptors. Finally, long-term regulation of both receptors stabilizes short-term desensitization for longer.
引用
收藏
页码:79 / 90
页数:12
相关论文
共 50 条
  • [41] Modified receptor internalization upon coexpression of 5-HT1B receptor and 5-HT2B receptors
    Janoshazi, Agnes
    Deraet, Maud
    Callebert, Jacques
    Setola, Vincent
    Guenther, Silke
    Saubamea, Bruno
    Manivet, Philippe
    Launay, Jean-Marie
    Maroteaux, Luc
    MOLECULAR PHARMACOLOGY, 2007, 71 (06) : 1463 - 1474
  • [42] Regulation of 5-HT2A receptor by chronic stress and antidepressants
    López, JF
    Zimmer, CA
    Vázquez, DM
    BIOLOGICAL PSYCHIATRY, 1999, 45 (08) : 91S - 91S
  • [43] Serotonin Receptor Activity Profiles (5-HT2B and 5-HT2A) for Nine Commercialized Ergot Alkaloids Correspond to Known Risks of Fibrosis and Hallucinations
    Alam, A.
    Alam, A.
    HEADACHE, 2019, 59 : 135 - 136
  • [44] Pharmacological characterization of mitogen-activated protein kinase activation by recombinant human 5-HT2C, 5-HT2A, and 5-HT2B receptors
    Knauer, Christopher S.
    Campbell, Jeffrey E.
    Chio, Christopher L.
    Fitzgerald, Lawrence W.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2009, 379 (05) : 461 - 471
  • [45] Evidence that the 5-HT2A and 5-HT2B receptor couple differently to the mitogen activated protein kinase pathway in smooth muscle contraction.
    Hongsakaphadana, A
    Watts, SW
    FASEB JOURNAL, 1998, 12 (04): : A151 - A151
  • [46] Selective impairment of spinal mu-opioid receptor mechanism by plasticity of serotonergic facilitation mediated by 5-HT2A and 5-HT2B receptors
    Aira, Zigor
    Buesa, Itsaso
    Garcia del Cano, Gontzal
    Salgueiro, Monika
    Mendiable, Nahia
    Mingo, Janire
    Aguilera, Luciano
    Bilbao, Juan
    Azkue, Jon Jatsu
    PAIN, 2012, 153 (07) : 1418 - 1425
  • [47] Pharmacological characterization of mitogen-activated protein kinase activation by recombinant human 5-HT2C, 5-HT2A, and 5-HT2B receptors
    Christopher S. Knauer
    Jeffrey E. Campbell
    Christopher L. Chio
    Lawrence W. Fitzgerald
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2009, 379 : 461 - 471
  • [48] Synthesis, affinity at 5-HT2A, 5-HT2B and 5-HT2C serotonin receptors and structure-activity relationships of a series of cyproheptadine analogues
    Honrubia, MA
    Rodriguez, J
    Dominguez, R
    Lozoya, E
    Manaut, F
    Seijas, JA
    Villaverde, MC
    Calleja, JM
    Cadavid, MI
    Maayani, S
    Sanz, F
    Loza, MI
    CHEMICAL & PHARMACEUTICAL BULLETIN, 1997, 45 (05) : 842 - 848
  • [49] 5-HT2B Receptor Antagonists Reduce Nerve Injury-Induced Tactile Allodynia and Expression of 5-HT2B Receptors
    Pineda-Farias, Jorge B.
    Velazquez-Lagunas, Isabel
    Barragan-Iglesias, Paulino
    Cervantes-Duran, Claudia
    Granados-Soto, Vinicio
    DRUG DEVELOPMENT RESEARCH, 2015, 76 (01) : 31 - 39
  • [50] Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells
    Porter, RHP
    Benwell, KR
    Lamb, H
    Malcolm, CS
    Allen, NH
    Revell, DF
    Adams, DR
    Sheardown, MJ
    BRITISH JOURNAL OF PHARMACOLOGY, 1999, 128 (01) : 13 - 20